-+ 0.00%
-+ 0.00%
-+ 0.00%

Wedbush Maintains Outperform on Avalo Therapeutics, Lowers Price Target to $20

Benzinga·11/06/2026 16:55:55
Listen to the news
Wedbush analyst Robert Driscoll maintains Avalo Therapeutics (NASDAQ:AVTX) with a Outperform and lowers the price target from $22 to $20.